Full 5-HT1A serotonin receptor agonist. Reduces hippocampal 5-HT levels following systemic administration in rats in vivo. More active enantiomer of 8-Hydroxy-DPAT hydrobromide.
|Storage||Desiccate at +4°C|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 328.29. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||3.05 mL||15.23 mL||30.46 mL|
|5 mM||0.61 mL||3.05 mL||6.09 mL|
|10 mM||0.3 mL||1.52 mL||3.05 mL|
|50 mM||0.06 mL||0.3 mL||0.61 mL|
References are publications that support the products' biological activity.
Bjork et al (1989) Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain. J.Med.Chem. 32 779 PMID: 2522991
Corrfield et al (1991) Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogues at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase. Mol.Pharmacol. 39 780 PMID: 1828859
Yoshitake and Kehr (2004) Differential effects of (R)-, (R, S)- and (S)-8-hydroxy-2-(di-n-propylamino)tetralin on hippocampal serotonin release and induction of hypothermia in awake rats. Life Sci. 74 2865 PMID: 15050424
If you know of a relevant reference for (R)-(+)-8-Hydroxy-DPAT hydrobromide, please let us know.
View Related Products by Product Action
Keywords: (R)-(+)-8-Hydroxy-DPAT hydrobromide, supplier, Selective, 5-HT1A, agonists, active, enantiomer, Serotonin, Receptors, 5-HT1A, Receptors, 5-HT1A, Receptors, Tocris Bioscience
3 Citations for (R)-(+)-8-Hydroxy-DPAT hydrobromide
Citations are publications that use Tocris products. Selected citations for (R)-(+)-8-Hydroxy-DPAT hydrobromide include:
Cassilly et al (2016) SB-224289 Antagonizes the Antifungal Mechanism of the Marine Depsipeptide Papuamide A. Psychopharmacology (Berl) 11 e0154932 PMID: 27183222
Wierońska et al (2015) The antipsychotic-like effects in rodents of the positive allosteric modulator Lu AF21934 involve 5-HT1A receptor signaling: mechanistic studies. Oncoscience 232 259 PMID: 25012236
Rossi et al (2008) Differential regulation of serotonin-1A receptor-stimulated [35S]GTP gamma S binding in the dorsal raphe nucleus by citalopram and escitalopram. Eur J Pharmacol 583 103 PMID: 18289523
Do you know of a great paper that uses (R)-(+)-8-Hydroxy-DPAT hydrobromide from Tocris? If so please let us know.
Reviews for (R)-(+)-8-Hydroxy-DPAT hydrobromide
There are currently no reviews for this product. Be the first to review (R)-(+)-8-Hydroxy-DPAT hydrobromide and earn rewards!
Have you used (R)-(+)-8-Hydroxy-DPAT hydrobromide?
Submit a review and receive an Amazon gift card.
$10US/$10CAN/€7/£6 gift card for a review without an image
$25US/$25CAN/€18/£15 gift card for a review with an image
*Offer only valid in the USA / Canada, UK and EuropeSubmit a Review
Literature in this Area
5-HT Receptors Scientific Review
Written by Nicholas M. Barnes and John F. Neumaier, this review summarizes the various serotonin receptor subtypes and their importance in mediating the role of serotonin in numerous physiological and pharmacological processes. Compounds available from Tocris are listed.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.